

**Reference Number:** FOI202223/254  
**From:** Private Individual  
**Date:** 23 August 2022  
**Subject:** Treatments and clinical trials relating to Myelofibrosis

Q1 Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

A1 Yes

Q2 Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).  
a. How many of these patients were above age 65?

A2 Zero

a. Not applicable, Alder Hey Children's NHS Foundation Trust does not treat patients above the age of 65

Q3 How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

A3 Not applicable, as per A2 above

Q4 How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

a. Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:  
I. Hydroxyurea  
II. Fedratinib  
III. Received No Treatment

A4 Zero

a. Not applicable

Q5 Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

A5 No – we do not have any trials running for myelofibrosis